tiprankstipranks
Advertisement
Advertisement

ARGX Stock Latest News

Argenx Earnings Call: Growth Momentum Meets Heavy Investment
Company AnnouncementsArgenx Earnings Call: Growth Momentum Meets Heavy Investment
4h ago
ARGX
Argenx price target raised to $1,025 from $945 at RBC Capital
PremiumThe Fly
Argenx price target raised to $1,025 from $945 at RBC Capital
9h ago
ARGX
Matt Phipps Reiterates Buy on argenx as Vyvgart Outperformance, Sustained Profitability and Late-Stage Pipeline Upside Remain Underappreciated
PremiumRatings
Matt Phipps Reiterates Buy on argenx as Vyvgart Outperformance, Sustained Profitability and Late-Stage Pipeline Upside Remain Underappreciated
15h ago
ARGX
Argenx reports Q2 EPS $7.32, consensus $6.94
PremiumThe Fly
Argenx reports Q2 EPS $7.32, consensus $6.94
15h ago
ARGX
Analyst Sees arGEN X’s Vyvgart Momentum and Strategic Positioning Driving Durable Growth; Maintains Buy Rating
PremiumRatings
Analyst Sees arGEN X’s Vyvgart Momentum and Strategic Positioning Driving Durable Growth; Maintains Buy Rating
2d ago
ARGX
Buy Rating on argenx Driven by Vyvgart’s Expanding Neuromuscular Franchise and Upcoming Phase III ALKIVIA Myositis Catalyst
PremiumRatingsBuy Rating on argenx Driven by Vyvgart’s Expanding Neuromuscular Franchise and Upcoming Phase III ALKIVIA Myositis Catalyst
2d ago
ARGX
Argenx price target raised to $1,182 from $1,152 at Citi
Premium
The Fly
Argenx price target raised to $1,182 from $1,152 at Citi
3d ago
ARGX
Is ARGX a Buy, Before Earnings?
Premium
Pre-Earnings
Is ARGX a Buy, Before Earnings?
3d ago
ARGX
Argenx Expands Efgartigimod Into Autoimmune Encephalitis With New POLARIS Study
PremiumCompany Announcements
Argenx Expands Efgartigimod Into Autoimmune Encephalitis With New POLARIS Study
4d ago
ARGX
William Blair healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
William Blair healthcare analysts hold an analyst/industry conference call
7d ago
ARGX
Argenx Targets Graves’ Disease With New Phase 3 Trial, Expanding Its Autoimmune Footprint
PremiumCompany Announcements
Argenx Targets Graves’ Disease With New Phase 3 Trial, Expanding Its Autoimmune Footprint
15d ago
ARGX
Argenx Targets Graves’ Disease With New Phase 3 Trial: What Investors Should Know
PremiumCompany Announcements
Argenx Targets Graves’ Disease With New Phase 3 Trial: What Investors Should Know
15d ago
ARGX
Argenx price target raised to $945 from $890 at RBC Capital
PremiumThe FlyArgenx price target raised to $945 from $890 at RBC Capital
17d ago
ARGX
Argenx price target raised to EUR 900 from EUR 750 at Deutsche Bank
Premium
The Fly
Argenx price target raised to EUR 900 from EUR 750 at Deutsche Bank
21d ago
ARGX
Argenx price target raised to $1,088 from $1,016 at BofA
Premium
The Fly
Argenx price target raised to $1,088 from $1,016 at BofA
22d ago
ARGX
Vyvgart’s INM Breakthrough and Multi‑Billion Sales Potential Drive Tazeen Ahmad’s Buy Rating on argenx and Price Target Increase to $1,088
PremiumRatings
Vyvgart’s INM Breakthrough and Multi‑Billion Sales Potential Drive Tazeen Ahmad’s Buy Rating on argenx and Price Target Increase to $1,088
22d ago
ARGX
Argenx added to Q3 Tactical Ideas List at Wells Fargo
PremiumThe Fly
Argenx added to Q3 Tactical Ideas List at Wells Fargo
23d ago
ARGX
Argenx Buy Rating Reiterated as Analyst Sees Undervalued Vyvgart Myositis Opportunity; $940 Price Target Maintained
PremiumRatings
Argenx Buy Rating Reiterated as Analyst Sees Undervalued Vyvgart Myositis Opportunity; $940 Price Target Maintained
29d ago
ARGX
Argenx price target raised to $1,180 from $1,170 at Morgan Stanley
PremiumThe Fly
Argenx price target raised to $1,180 from $1,170 at Morgan Stanley
30d ago
ARGX
Argenx Showcases Autoimmune Myositis R&D in June 23 FcRn Webinar
PremiumCompany AnnouncementsArgenx Showcases Autoimmune Myositis R&D in June 23 FcRn Webinar
1M ago
6K
ARGX
Douglas Tsao Reiterates Buy on argenx, Keeps $940 Price Target on Durable Vyvgart Data and Upcoming Phase 3 Catalysts
Premium
Ratings
Douglas Tsao Reiterates Buy on argenx, Keeps $940 Price Target on Durable Vyvgart Data and Upcoming Phase 3 Catalysts
2M ago
ARGX
Argenx Showcases Durable VYVGART Benefits in Myositis and Sjogren’s at EULAR 2026
Premium
Company Announcements
Argenx Showcases Durable VYVGART Benefits in Myositis and Sjogren’s at EULAR 2026
2M ago
6K
ARGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >